Obesity

Generic semaglutide market shows signs of excess inventory bulge

Distributors grapple with rising semaglutide inventory amid slower liquidation

India's GLP-1 market enters slower growth phase after semaglutide surge

After a near fourfold expansion driven by generic semaglutide launches, India's GLP-1 market is showing signs of moderation as patient onboarding growth slows

Next-gen obesity drug curbs sleep apnea, aids weight loss: Eli Lilly

In a Phase 3 trial, Lilly found a weekly injection of retatrutide reduced moderate-to-severe obstructive sleep apnea severity by 60.6 per cent in adults with obesity

Eli Lilly and Novo Nordisk looking beyond US for obesity drug growth

Novo Nordisk and Eli Lilly are expanding obesity drug access globally as demand grows beyond the US and cheaper semaglutide generics enter new markets

Alkem launches semaglutide pre-filled syringes in India at ₹350

The company has received DCGI approval for multiple dosage strengths and aims to widen access to semaglutide treatment for diabetes and obesity

Worsening side effects of life in fast lane: Obesity, diabetes up sharply

Lifestyle diseases on the rise, shows NFHS-6, though insurance coverage, vaccination rates, maternal care, child health indicators have improved

France becomes first EU country to reimburse anti-obesity drugs: Minister

Patients in France are currently paying around €300 ​per month on average for the drugs, she said, without indicating how many people currently follow such treatments

CDSCO asks states, UTs to monitor surrogate promotion for GLP-1 drugs

CDSCO has directed states and UTs to curb surrogate advertising of GLP-1 obesity drugs amid rising sales and aggressive awareness campaigns

India joins weight-loss drug race, but affordability remains a concern

India is in the race for a new class of weight-loss drugs, but the question is: Will they be affordable?

How Chinese oral GLP-1 drugs may reshape India's obesity drug market

With cheaper GLP-1 pills entering India, access could improve significantly, but experts warn that affordability must be balanced with strong regulation and patient safety

GLP-1 sees strong return dosage in China and Japan as India lags on value

Global drugmakers are prioritising China and Japan for GLP-1 investments due to stronger pricing power and adoption, while India remains a large but price-sensitive market with slower premium uptake

Semaglutide generics hit Mounjaro sales, market share after patent expiry

Generic semaglutide surge dents Mounjaro sales, reshaping India's fast-growing GLP-1 diabetes and obesity drug market

Emcure slashes obesity drug Poviztra price by up to 55% amid competition

Emcure cuts Poviztra prices by up to 55% following Novo Nordisk's move, lowering monthly treatment costs for semaglutide-based obesity therapy in India

Mann Ki Baat: PM Modi urges people to reduce sugar intake to avoid obesity

Prime Minister Narendra Modi on Sunday urged citizens to reduce their sugar intake and cut down on cooking oil by 10 per cent, saying such small efforts will keep people away from obesity and lifestyle diseases. In his monthly radio address, 'Mann Ki Baat', Modi said many people have commented on Instagram content creator Yuvraj Dua's post, in which he had requested the prime minister to ask his father to reduce his sugar intake. "I am happy that my request had a positive impact on his father. I would urge all of you to reduce your sugar intake, and as I have said earlier, we also need to cut down on cooking oil by 10 per cent. These small efforts will keep you away from obesity and lifestyle diseases," Modi said. The prime minister said he has always urged everyone to pay attention to fitness. "Now, less than 100 days are left for International Yoga Day; the attraction towards yoga is also rising continuously all over the world. Almis Ji is promoting yoga through his Arvind Yoga .

Effective oversight: Safety crucial for success of weight-loss drugs

According to the National Family Health Survey 2019-21, 24 per cent of Indian women and 23 per cent of Indian men are overweight

Govt intensifies checks on illegal sale, misuse of GLP-1 weight-loss drugs

As cheaper GLP-1 weight-loss drugs flood India after patent expiry, the government has intensified surveillance to curb illegal sales, misleading promotion, and unsafe use without medical supervision

Semaglutide generics may fuel rush for cosmetic weight loss, warn doctors

As semaglutide goes off patent, doctors warn of misuse by non-obese individuals amid rising demand driven by social media and lower-cost generics

Bracing for a flood of semaglutide generics, Novo holds the price line

Novo Nordisk says competition in semaglutide will be driven by science and quality, not pricing, as multiple generic versions prepare to enter India after patent expiry

Fake obesity drugs are booming globally: Lancet report raises alarm

A Lancet report warns counterfeit weight-loss injections like Ozempic and Mounjaro are spreading globally, driven by high demand and prices, raising serious risks for patients

Ozempic patent expiry set to trigger weight-loss drug boom in India

India is the first major country after Canada where Novo is losing patent on semaglutide and will see an onslaught of generic versions